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bjectives Using optical coherence tomography, we assessed the proportion of uncovered struts at
-month follow-up in zotarolimus-eluting stents (ZES), speciﬁcally Endeavor (Medtronic CardioVascular,
anta Rosa, California) stents, and identical bare-metal stents (BMS) implanted in patients with ST-seg-
ent elevation myocardial infarction (STEMI).
ackground Sirolimus- and paclitaxel-eluting stents implanted in STEMI have been associated with
elayed healing and incomplete strut coverage. ZES are associated with a more complete and uni-
orm strut coverage in stable patients, but whether this holds true also after STEMI is unknown.
ethods Forty-four patients with STEMI who underwent primary PCI were randomized to ZES or
MS (3:1 randomization). Angiographic, intravascular ultrasound, and optical coherence tomography
ollow-up was conducted at 6 months and clinical follow-up at 1 year. All images were analyzed by
n independent core laboratory that was blind to stent assignments.
esults There were no differences between ZES and BMS in percentage of uncovered struts (median:
.00% [interquartile range (IQR): 0.00% to 1.78%] vs. 1.98% [IQR: 0.21% to 7.33%], p  0.13), maximum
ength of uncovered segments (0.00 [IQR: 0.00 to 1.19] mm vs. 1.38 [IQR: 0.65 to 3.30] mm, p  0.10),
ercentage of malapposed struts (0.00% [IQR: 0.00% to 0.23%] vs. 0.15% [IQR: 0.00% to 5.81%], p  0.16),
nd maximum length of malapposed segments (0.00 [IQR: 0.00 to 0.67] mm vs. 0.33 [IQR: 0.00 to 2.55]
m, p  0.20). Neointimal response was similar between ZES and BMS (332 [IQR: 240 to 429] m vs.
86 [IQR: 136 to 348] m, p  0.99) and evenly distributed. No late acquired malapposition was ob-
erved in both groups. There were no deaths, myocardial infarction, or stent thromboses at 1 year.
onclusions This optical coherence tomography study found no difference in strut coverage and
imilar vessel response to ZES, when compared with identical BMS, implanted during primary percu-
aneous coronary intervention in STEMI patients. (Six-Month Coverage and Vessel Wall Response of
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681rug-eluting stents (DES) reduce neointimal hyperplasia
1,2) in comparison to bare-metal stents (BMS), but de-
ayed healing in DES has been reported in autopsy regis-
ries, mainly in patients treated during acute ST-segment
levation myocardial infarction (STEMI) (3). The underly-
ng necrotic core and intracoronary thrombus may increase
he number of uncovered stent struts and possibly increase
he incidence of DES late stent thrombosis (3,4). Optical
oherence tomography (OCT) provides unique in vivo
nsights into stent strut coverage (5–7), and local relation-
hip with thrombus formation (8). Nonrandomized OCT
tudies have found fewer uncovered struts in zotarolimus-
luting stents (ZES) compared with first-generation DES
n stable angina and acute coronary syndrome (9), but it is
till unknown if ZES implanted during primary percutane-
us coronary intervention (PCI) would result in similar
tent strut coverage as that of BMS. Therefore, we designed
prospective, randomized, controlled study to assess the
-month stent coverage in consecutive STEMI patients
andomly treated with the Endeavor ZES (Medtronic
ardioVascular, Santa Rosa, California) or identical BMS
Driver, Medtronic CardioVascular) by using OCT.
ethods
tudy design, patients, and procedures. The OCTAMI
Optical Coherence Tomography in Acute Myocardial In-
arction) trial was designed as a single-center, prospective,
andomized, controlled study with imaging analyses per-
ormed by an independent core laboratory (Cardiovascular
maging Core Laboratory, University Hospitals Case Med-
cal Center, Cleveland, Ohio). Core laboratory personnel
ere blinded to the treatment assignment.
Consecutive eligible patients were randomized to stent
mplantation with ZES or otherwise equivalent BMS in a
:1 ratio. Only a single type of stent was allowed in each
atient. The study protocol was approved by the local
thical committee with all patients providing written in-
ormed consent. Eligible patients presented with STEMI
12 h after symptom onset (prolonged chest pain for more
han 20 min, unresponsive to nitroglycerin, and ST-
egment elevation of at least 1 mm in 2 or more contiguous
eads, or true posterior myocardial infarction), an infarct
rtery in a native coronary vessel with 70% diameter
tenosis, a reference vessel diameter of 2.5 to 3.75 mm, and
nderwent primary PCI with stent implantation. Patients
ith left main disease, infarct lesions in bypass grafts,
ardiogenic shock, renal failure, recent major bleeding,
llergy to aspirin or clopidogrel, on anticoagulant therapy, or
ith no suitable anatomy for OCT (ostial lesions, extreme
ortuosity, and large vessels 3.75 mm in diameter) were
xcluded.
Percutaneous coronary intervention was performed ac-
ording to standard techniques. Direct stenting, thrombus tspiration, and use of glycoprotein IIb/IIIa inhibitors were
llowed and left to the operator’s discretion. All patients
ere pre-treated with aspirin 250 mg intravenously and
lopidogrel 300 mg orally before PCI, followed by daily
dministration of clopidogrel 75 mg for at least 6 months
fter discharge and aspirin indefinitely. During PCI, pa-
ients received unfractionated heparin to maintain an acti-
ated clotting time of 300 s or more. Patients were read-
itted for planned imaging follow-up at 6 months.
uantitative coronary angiography. Quantitative coronary
ngiograms at baseline, immediately after PCI, and at
ollow-up were performed in at least 2 orthogonal views
fter 200 g of intracoronary nitroglycerin. Digital coronary
ngiograms were analyzed off-
ine at the core laboratory with a
alidated automated edge detec-
ion system (CAAS II, PIE
edical, Maastricht, the Neth-
rlands). Angiographic measure-
ents were made in the same 2
rojections at pre-PCI, post-
CI, and follow-up. The stented
egment plus 5-mm distal and
roximal edges were selected for
nalysis. Reference vessel diam-
ter, minimum luminal diame-
er, percent diameter stenosis,
nd lesion length were obtained.
ate lumen loss was calculated
s the change in MLD from
ost-procedure to follow-up. Bi-
ary angiographic restenosis was
efined as diameter stenosis
50% at 6-month follow-up.
ntravascular ultrasound (IVUS).
VUS was performed post-PCI
nd at 6-month follow-up using a
0-MHz Atlantis SR Pro cathe-
er (Boston Scientific, Fremont,
alifornia). The IVUS imaging
as carried out with motorized
ullback at 1 mm/s to include the stent and at least 5 mm
roximal and distal to the stent. All IVUS data were digitally
tored for independent quantitative and qualitative analyses at
he Core Laboratory with validated detection software (Curad,
ersion 4.32, Wijk bij Duurstede, the Netherlands). Quanti-
ative analysis included measurements every 0.5 mm of the
xternal elastic membrane (EEM), stent, and lumen cross-
ectional area (CSA). Plaque plus media CSA was counted as
EM minus lumen. Neointimal hyperplasia (NIH) was cal-
ulated as the difference between stent and lumen. Percent
IH volume obstruction was computed as NIH divided by
tent volume. Qualitative analysis included stent malapposi-
Abbreviations
and Acronyms
AIT  abnormal intraluminal
tissue
BMS  bare-metal stent(s)
CSA  cross-sectional area
DES  drug-eluting stent(s)
EEM  external elastic
membrane
IVUS  intravascular
ultrasound
NIH  neointimal hyperplasia
OCT  optical coherence
tomography
PCI  percutaneous
coronary interventions
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
SIT  strut-level intimal
thickness
STEMI  ST-segment
elevation myocardial
infarction
ZES  zotarolimus-eluting
stent(s)ion, defined as blood speckle behind stent struts categorized as
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682ersistent (visible at post-procedure and follow-up), resolved
visible only at post-procedure), and late acquired (visible only
t follow-up).
ptical coherence tomography. The OCT imaging was
btained at 6-month follow-up and performed after intra-
oronary nitroglycerin injection. A time domain OCT
ystem (M2CV OCT Imaging System, LightLab Imaging,
estford, Massachusetts) was used. The occlusive tech-
ique was adopted to completely remove blood from the
rtery (6). Images were acquired with an automated pull-
ack at a rate of 1.0 mm/s, then digitally stored and
ubmitted to the core laboratory for offline evaluation and
ubsequent analyses. All cross-sectional images (frames)
ere initially screened for quality assessment and excluded
rom analysis if any portion of the image was out of the
creen, a side branch occupied 45° of the cross-section, or
he image had poor quality caused by residual blood, sew-up
rtifact, or reverberation (10). Strut-level analysis was per-
ormed considering all analyzable frames (0.06-mm inter-
als) along the entire target segment. A dedicated auto-
ated contour-detection system (OCT system software
ersion B.0.1, LightLab Imaging) developed in collabora-
ion with the Imaging Core Laboratory was used for
easurements. Lumen, stent, and NIH areas and volumes
ere calculated in a similar fashion of IVUS methodology at
Table 1. Baseline Clinical and Procedural Characteristics
ZES
(n  33)
BMS
(n  11)
p
Value
Age, yrs 61.1 11.4 61.1 12.4 0.99
Male sex 25 (75.8) 9 (81.8) 1.00
Diabetes mellitus 4 (12.1) 2 (18.2) 0.63
Hypertension 16 (48.4) 6 (54.6) 1.00
Hyperlipidemia 10 (30.3) 7 (63.6) 0.08
Current smoker 23 (69.7) 6 (54.5) 0.47
Prior myocardial infarction 3 (9.1) 1 (9.1) 1.00
Prior PCI 3 (9.1) 1 (9.1) 1.00
Symptoms onset to PCI, h 3.6 2.5 3.2 1.5 0.62
Infarct-related artery
Left anterior descending 12 (36.4) 2 (18.2) 0.46
Left circumﬂex 5 (15.1) 2 (18.2) 1.00
Right coronary artery 16 (48.5) 7 (63.6) 0.49
Initial TIMI ﬂow grade 0/1, 2, 3, % 53, 25, 22 50, 30, 20 1.00
Post-PCI TIMI ﬂow grade 0/1, 2, 3, % 0, 6, 94 0, 10, 90 1.00
Thrombus aspiration 7 (21) 4 (36) 0.31
Direct stenting 15 (45.4) 4 (36.4) 0.73
Maximum balloon pressure at implant, atm 17.5 2.4 18.3 2.3 0.34
Post-dilation 15 (45.5) 7 (63.6) 0.49
Data presented as n (%) ormean SD unless otherwise noted. The following tests were used: for
categorical variables, Fisher exact; for ordinal variables, Mann-Whitney U; and for continuous
variables, analysis of variance or Wilcoxon rank sum.
BMS bare-metal stent(s); PCI percutaneous coronary intervention; TIMI Thrombolysis In
Myocardial Infarction; ZES zotarolimus-eluting stent(s)..5-mm intervals. A strut was considered suitable fornalysis only if it had: 1) well-defined bright “blooming”
ppearance; and 2) characteristic shadow perpendicular to
he light source. The inner and outer contours of each strut
eflection (blooming) were delineated semiautomatically.
he center of the luminal surface of the strut blooming was
etermined for each strut and its distance to the lumen
ontour was calculated automatically to determine strut-
evel intimal thickness (SIT). Struts covered by tissue had
ositive SIT values, whereas protruding uncovered struts or
alapposed struts had negative SIT values. Data were
tored in an integrated database system, which corrects for
trut thickness of different stent types once the study is
ompleted and data are locked, thus allowing for blinding of
he readers. Strut malapposition was determined when the
egative value of SIT was higher than the strut thickness,
ccording to each stent manufacturer’s specifications, with
ddition of a compensation factor of 20 m to correct for
trut blooming. The blooming compensation factor was
etermined based on analysis of 2,250 struts. To determine
eproducibility of OCT measurements, quantitative analyses
n 333 struts were performed by 2 independent analysts and
ere repeated 3 months after the initial analysis. The
ifference in SIT measurements between 2 analysts was 0.01
0.02 m (r  0.997). Highly reproducible measurements
or strut apposition and coverage using the described meth-
dology have been reported (11). Qualitative imaging as-
essment was performed in every frame for presence of
Table 2. Baseline and Follow-Up Quantitative Coronary Angiographic
Analysis
ZES
(n  32)
BMS
(n  10)
p
Value
Pre-procedure
RVD, mm 2.81 (2.42 to 3.32) 3.10 (2.82 to 3.68) 0.31
MLD, mm 0.26 (0.00 to 0.89) 0.04 (0.00 to 0.70) 0.53
DS, % 92.0 (68.5 to 100.0) 98.5 (81.0 to 100.0) 0.36
Lesion length, mm 19.5 (10.4 to 25.5) 15.8 (10.3 to 22.9) 0.29
Post-PCI
In-stent MLD, mm 2.80 (2.57 to 3.08) 2.70 (2.49 to 2.86) 0.80
In-lesion MLD, mm 2.42 (1.88 to 2.72) 2.39 (2.04 to 2.65) 0.92
In-lesion acute gain, mm 1.86 (1.52 to 2.33) 2.03 (1.82 to 2.40) 0.52
In-stent DS, % 10.00 (7.0 to 16.5) 12.0 (9.0 to 17.0) 0.64
Stent length, mm 26.3 (17.2 to 36.3) 21.1 (15.8 to 23.7) 0.01
Follow-up
In-stent MLD, mm 2.18 (1.76 to 2.33) 2.24 (1.55 to 2.60) 0.84
In-lesion MLD, mm 2.05 (1.72 to 2.27) 2.21 (1.82 to 2.41) 0.36
In-stent DS, % 27.5 (20.5 to 39.5) 37.0 (21.0 to 51.0) 0.32
In-stent late loss, mm 0.59 (0.33 to 0.97) 0.70 (0.06 to 1.13) 0.78
In-lesion late loss, mm 0.26 (–0.06 to 0.71) 0.34 (–0.01 to 0.48) 0.83
In-stent binary restenosis 4 (12.5) 3 (30.0) 0.33
Categorical variables are presented as n (%), and ordinal and continuous variables are presented
as median (interquartile range). Test for comparison between 2 stent types: nonparametric
Mann-Whitney U for continuous or ordinal variables, and Fisher exact for categorical variables.
DS diameter stenosis; MLDminimum lumen diameter; RVD reference vessel diameter;other abbreviations as in Table 1.
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683bnormal intraluminal tissue (AIT). We defined AIT as any
ass protruding beyond the stent struts into the lumen,
ith irregular surface and a sharp intensity gap between mass
nd neointimal (12,13). Interobserver and intraobserver vari-
bility showed substantial agreement for AIT qualitative as-
essment (kappa  0.755 and 0.885, respectively).
linical follow-up and end points. Clinical follow-up was
erformed at 1, 6, and 12 months in all patients to assess the
ccurrence of major adverse cardiac events (defined in
nline Appendix), including cardiac death, reinfarction,
troke, and target lesion and target vessel revascularization.
he incidence of stent thrombosis was also evaluated per the
cademic Research Consortium’s definitions of definite/
robable (14).
The primary end point was the percentage of uncovered
tent struts at 6 months. Secondary imaging end points
ncluded the rate of apposed strut without neointima,
ercentage malapposed struts without neointima, percent-
ge net volume obstruction by OCT, and rate of late
cquired malapposed struts as determined by IVUS.
tatistical methods. Data are expressed as median (inter-
uartile) for continuous variables, and ordinal variables and
ercentages for categorical variables. The differences be-
ween treatment groups were evaluated by analysis of
ariance or Wilcoxon rank sum scores for continuous
ariables, if appropriate. Fisher exact test was utilized for the
nalysis of categorical variables and Mann-Whitney U test
Table 3. OCT Quantitative and Qualitative Analysis a
Strut-level analysis
Struts/patient, n 3
Analyzed struts/cross-section, n
Uncovered struts, %
Uncovered, nonmalapposed struts, %
Uncovered, malapposed struts, %
Stent with 10% uncovered struts
Maximum length of uncovered segment, mm
Maximum length of malapposed segment, mm
Neointimal hyperplasia, m
AIT related with uncovered strut
AIT related with malapposed strut
Planar and volumetric analysis
Stent area, mm2
Lumen area, mm2
Neointimal area, mm2
Stent volume, mm3 2
Lumen volume, mm3 1
Neointimal volume, mm3
Net volume obstruction, % 3
Categorical variables are presented as n (%), andordinal and continuou
between 2 stent types: nonparametric Mann-Whitney U for continuouAIT abnormal intraluminal tissue; OCT optical coherence tomography;as used for ordinal variables. All statistical analyses were
erformed with the use of SAS software (version 9.1, SAS
nstitute, Cary, North Carolina), and all reported p values
re 2-sided. The null hypothesis was of no difference in
-month percentage of uncovered stent struts, with an
lternative hypothesis of lower rate of uncovered struts in
he ZES group. Due to unavailability of OCT data on ZES
overage in STEMI, no evidence-based power calculation
as possible at the time of the study design. Nonetheless,
e envisioned that, expecting a 2.0  5.0% versus 6.0 
.0% rate of uncovered stent struts at 6 months, and aiming
or a 5% 2-tailed alpha and 90% power, at least 44 patients
ere needed with an allocation ratio of 3:1.
esults
etween April and October 2008, 44 consecutive eligible
atients were randomly assigned to the 2 treatment groups
33 to ZES and 11 to BMS), with all patients receiving the
llocated stent and none crossing over to the other stent
roup. All 44 patients had a primary PCI procedure with
uccessful stent implantation (47 ZES and 12 BMS); 42 of
4 enrolled patients had follow-up imaging at 6 months
96%) as required by protocol, with 2 asymptomatic patients
efusing to return for elective control. There were no
ignificant differences between groups on baseline clinical
nd procedural characteristics (Table 1).
nth Follow-Up
ZES
 32)
BMS
(n  10) p Value
743 to 4,742) 2,518 (1,935 to 3,386) 0.003
06 to 10.06) 8.79 (8.52 to 9.32) 0.79
to 1.78) 1.98 (0.21 to 7.33) 0.14
to 0.85) 0.31 (0.21 to 6.05) 0.16
to 0.23) 0.15 (0 to 5.81) 0.16
1) 2 (20.0) 0.14
to 1.19) 1.38 (0.65 to 3.30) 0.10
to 0.67) 0.33 (0 to 2.55) 0.20
0 to 429) 186 (136 to 348) 0.99
1) 1 (10.0) 0.42
4) 2 (20.2) 0.58
11 to 10.29) 7.56 (7.18 to 9.05) 0.93
23 to 6.63) 5.91 (4.58 to 7.52) 0.57
28 to 3.83) 1.79 (0.61 to 2.82) 0.33
0.8 to 319.5) 171.4 (121.4 to 234.0) 0.13
3.6 to 212.7) 115.8 (76.4 to 183.3) 0.38
.3 to 114.3) 38.3 (14.0 to 51.4) 0.09
.19 to 45.77) 22.26 (8.26 to 38.06) 0.53
les are presented asmedian (interquartile range). Test for comparison
inal variables, and Fisher exact for categorical variables.t 6-Mo
(n
,469 (2,
8.61 (8.
0 (0
0 (0
0 (0
1 (3.
0 (0
0 (0
332 (24
1 (3.
3 (9.
8.18 (7.
5.73 (4.
2.78 (2.
13.5 (16
50.9 (10
85.2 (47
6.28 (24
s variab
s or ordother abbreviations as in Table 1.
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684uantitative coronary angiography. Pre- and post-intervention
ngiographic measurements were similar for ZES and BMS
Table 2). However, stent length was higher in ZES compared
ith BMS (28.3 12.9 vs. 20.3 5.9, p 0.01). In-stent late
umen loss did not differ between groups.
CT analysis. Of 20,337 total frames collected by OCT,
7,088 (84%) were analyzed. Frames were excluded from
nalysis because of either bifurcation location (2,049;
0.1%) or any image artifact (1,200; 5.9%). At 6 months, on
per-patient basis, no significant difference was observed
etween ZES and BMS in percentage of uncovered struts
median: 0.00% [0.00% to 1.78%] vs. 1.98% [0.21% to
.33%], p  0.13) (Table 3) (Fig. 1). In addition, no
ifferences were observed for both uncovered apposed and
alapposed struts (0.0% vs. 0.3%, p  0.16; 0.0% vs. 0.2%,
 0.16, respectively), as well as for maximum lengths of
ncovered (0.00 mm vs. 1.38 mm, p  0.10) and malap-
osed segments (0.00 mm vs. 0.33 mm, p  0.20). Simi-
arly, homogeneous coverage was observed along the entire
ength of the stent for ZES and BMS (p  0.16) (Fig. 2).
trut-level neointimal thickness and percent volume ob-
truction also did not differ between groups. Frequency of
IT related with uncovered and malapposed struts were
imilar between ZES and BMS (3.1% vs. 10%, p  0.42;
.4% vs. 20.2%, p  0.58, respectively).
VUS analysis. Table 4 shows that IVUS data were similar
etween the groups at post-procedure and 6-month follow-
Figure 1. Distribution of Stent Strut Coverage in STEMI Patients
Distribution of percentage strut coverage measured by optical coherence tom
patients treated with bare-metal stents (n  10) (solid bars) and zotarolimus-
zotarolimus-eluting stents and bare-metal stents (p  0.14). No speciﬁc cutoff
support from previous validation studies of any speciﬁc threshold.p. The median net volume obstruction was 24.4% for ZES (nd 15.1% for BMS (p 0.21). The increase in mean EEM
SA observed after ZES implantation (but not after BMS)
id not result in any late acquired stent malapposition.
linical outcomes. Clinical follow-up was complete in all
atients at 1 year. There were no episodes of death,
yocardial infarction, or stent thrombosis. The total major
dverse cardiac events rate was 11.4% (5 of 44) and included
target lesion revascularizations (2 in ZES, 1 in BMS) and
target vessel revascularizations (ZES), with no statistically
ignificant differences between the groups.
iscussion
his OCT study found similar strut coverage and vessel
esponse in ZES compared with an identical BMS im-
lanted during primary PCI. The main findings were the
ollowing: 1) ZES, compared with BMS, had a similar
ncidence of uncovered struts, with stent strut coverage
venly distributed and greater than 98% at 6-month follow-
p; 2) the rate of strut malapposition with ZES was 1%
ith no late acquired malapposition; 3) no difference in
IH area and percentage area obstruction were measured by
CT strut-level analysis; and 4) similarly low rates of AIT
ssociated with uncovered and malapposed struts were
bserved in ZES and BMS.
Several studies support the mid-term safety of first-
eneration DES use in acute myocardial infarction
y at 6 months, in ST-segment elevation myocardial infarction (STEMI)
stents (n  32) (open bars). Similar distribution was observed for
ptimal” stent strut coverage was chosen given the lack of reliable data inograph
eluting
for “o1,2,15,16). However, their long-term safety has been ques-
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685ioned (3,17). In animal models, endothelialization has been
hown to occur earlier and more homogeneously in ZES
han in sirolimus-eluting stents (SES) and paclitaxel-eluting
tents (PES) with less inflammatory response and fibrin
dhesion on strut surface (18,19). Further, tests of endothe-
ial function suggested normal vasodilatory response by 28
ays with ZES and BMS, whereas endothelial dysfunction
p to 6 months after implantation has been observed with
ES and PES (20,21).
Optical coherence tomography allows accurate in vivo
trut-level analysis to measure completeness of stent cover-
ge and amount of neointima in DES (5,11,22,23). Unlike
athology that selectively analyzes cross-sections every 2 to
mm, OCT can collect data every 0.06 mm, making
ossible a more meticulous assessment of the heterogeneity
n strut coverage (10). Few OCT data regarding DES
mplanted during primary PCI are available. Sirolimus-
luting stent implanted in STEMI was identified as an
ndependent predictor of uncovered/malapposed struts at
-month OCT (24). The 13-month coverage of PES
mplanted in STEMI was assessed in 118 consecutive
atients from the HORIZONS-AMI (Harmonizing Out-
omes with Revascularization and Stents in Acute Myocar-
Figure 2. Longitudinal Pattern of Percentage Strut Coverage Between
2 Stent Types
Longitudinal pattern of percentage strut coverage, measured by optical
coherence tomography within bare-metal stents (n  10) (solid bars) and
zotarolimus-eluting stents (n  32) (open bars) at 6-month follow-up. The
evaluation compared data for 10 subsegments covering the length of
stents. The rate of coverage in different subsegments along the stent does
not change signiﬁcantly in zotarolimus-eluting stents (p  0.98) and bare-
metal stents (p  0.41). No difference was detected in percentage of cov-
erage between 2 stent types with linear mixed model (p  0.16), after
adjusting for the subsegments effect.ial Infarction) trial (25). Guagliumi et al. (25) found that sES resulted in a significantly higher rate of uncovered and
alapposed stent struts than BMS.
In the present study, ZES resulted in a very low rate of
ncovered struts and length of uncovered segment, which is
imilar to BMS results. Of note, these high rates of strut
overage were observed at 6-month follow-up. A recent
CT study in non-STEMI patients (9) showed almost
omplete neointimal coverage at 9 months in ZES, with a
ery low rate (0.3%) of uncovered struts and absence of
hrombus. As opposed to SES, ZES showed similar cover-
ge independent of clinical presentation (26). Our results
onfirm that coverage of ZES is similar in STEMI to that
bserved in non-STEMI patients.
The amount and distribution of NIH observed with ZES
n this study is consistent with the neointima response
eported in previous IVUS studies in non-STEMI patients
27,28). Specifically, NIH was similar in ZES and BMS as
etermined by both IVUS and OCT, with concordant
ndings of similar rates of repeat revascularization in ZES
nd BMS. The relationship among neointimal thickness,
ncovered struts, and local thrombus formation has also
een recently addressed by OCT following SES implanta-
ion (8,29). Although the number of uncovered struts and
he uneven NIH were determinant factors for local throm-
us formation, the degree of neointimal growth, as mea-
ured by OCT, had no influence on subclinical thrombus.
ur data suggested that neointimal coverage in ZES im-
lanted in STEMI was evenly distributed within the stent,
hus suggesting a contrast with the uneven neointimal
ormation observed with first-generation DES (17). Ac-
ordingly, the incidence of AIT related to uncovered struts
n ZES was equally low.
The clinical association between late acquired malappo-
ition in DES and subsequent stent thrombosis remains
ontroversial. Nevertheless, malapposed struts associated
ith positive remodeling has been recently associated with
ate stent thrombosis (30). In the present study, the increase
n mean EEM CSA observed after ZES implantation (but
ot after BMS) did not result in IVUS late acquired
alapposition, and 1% of ZES struts were malapposed at
-month by OCT.
tudy limitations. Strut coverage assessed by intravascular
CT must be interpreted with caution as it does not have
ndothelial cell level resolution or provide functional tissue
ifferentiation. Furthermore, current OCT systems cannot
ifferentiate between very small amounts of thrombus or
brin deposition, or even inflammatory cellular response
rom the underlying NIH. This study enrolled a very small
roup of patients, and it was not powered to investigate the
elationship between OCT findings and clinical outcomes.
o address the limitation due to the industry sponsorship of
he study, the investigators had full control in data analysis
nd final decision in the manuscript text, including re-
ponses to reviewers. Finally, pre-PCI or post-PCI OCT
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686as not performed, mainly for concerns about patient safety,
hus limiting our ability to appraise the impact of plaque
ype or early procedural results on 6-month vessel responses.
onclusions
his OCT study found similar 6-month strut coverage and
essel response in ZES and BMS implanted during primary
CI. Long-term follow-up in more patients is required to
stablish the clinical significance of these imaging findings
egarding stent thrombosis and restenosis.
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APPENDIX
or definitions of major adverse cardiac events, please see online version
f this article.
